Senate Reform Bill Includes Tax Credit For Dx, Drug-Delivery Investments
This article was originally published in The Gray Sheet
Companies with 250 or fewer employees would be eligible for a 50% tax credit on 2009-2010 investments in certain diagnostics, drug-delivery devices and pharmaceuticals under a provision in the Senate's health care reform bill
You may also be interested in...
Diagnostics firms stand to benefit most among medical device companies from $1 billion in life sciences innovation tax credits approved earlier this year, according to AdvaMed
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.